Dearborn and Dyehardt (D&D) has just put Forzosein on the market, a new compound that may be able to save the lives of people who suffer from cancer. D&D charges hundreds of times what it cost the company to make Forzosein to recoup the extremely high R&D expenses it bore to test the compound and get it approved. Darren Talbot is an executive in the Baldwin Corporation, the company that distributes Forzosein for D&D. Doctors say that Anna Bryan suffers from a rare form of cancer and has just a few months to live. Forzosein is a controversial choice for treating her cancer and is not covered by Amalgamated, her insurance company. To have hope for recovery Anna will need as many as 40 doses, but each dose of Forzosein costs $10,000. Anna is just 36 years old and has three young children. Her husband, Lester, asked D&D if it could make an exception in Anna’s case and charge less for the drug, but the company refused. He pleaded with Amalgamated to expand its coverage but it turned him down. He tried to take out a loan from the Tarrytown Bank, using his house as collateral, but the maximum amount the bank would loan him was $25,000. He went to friends and family to borrow money and raised an additional $15,000. Desperate, he begged Darren for the doses of Forzosein he needed for his wife. He would hand over the $40,000 he had raised and try, if he could, to pay the rest later. What should Darren do?